CO6160305A2 - Anticuerpos humanos de alta afinidad para el receptor de il-4 humano - Google Patents

Anticuerpos humanos de alta afinidad para el receptor de il-4 humano

Info

Publication number
CO6160305A2
CO6160305A2 CO09044043A CO09044043A CO6160305A2 CO 6160305 A2 CO6160305 A2 CO 6160305A2 CO 09044043 A CO09044043 A CO 09044043A CO 09044043 A CO09044043 A CO 09044043A CO 6160305 A2 CO6160305 A2 CO 6160305A2
Authority
CO
Colombia
Prior art keywords
human
seq
receiver
antibody
high affinity
Prior art date
Application number
CO09044043A
Other languages
English (en)
Spanish (es)
Inventor
Sean Stevens
Tammy Huang
Joel H Martin
Jeanette Fairhurst
Ashique Rafique
Marcela Torres
Kevin Pobursky
Raymond Leidich
Joan Windsor
Warren Mikulka
Diana Ahrens
Ergang Shi
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CO6160305A2 publication Critical patent/CO6160305A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
CO09044043A 2006-10-02 2009-04-30 Anticuerpos humanos de alta afinidad para el receptor de il-4 humano CO6160305A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84869406P 2006-10-02 2006-10-02
US95773807P 2007-08-24 2007-08-24

Publications (1)

Publication Number Publication Date
CO6160305A2 true CO6160305A2 (es) 2010-05-20

Family

ID=39344836

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09044043A CO6160305A2 (es) 2006-10-02 2009-04-30 Anticuerpos humanos de alta afinidad para el receptor de il-4 humano

Country Status (34)

Country Link
US (4) US7605237B2 (cg-RX-API-DMAC7.html)
EP (3) EP3845563A3 (cg-RX-API-DMAC7.html)
JP (1) JP2010505418A (cg-RX-API-DMAC7.html)
KR (1) KR101474227B1 (cg-RX-API-DMAC7.html)
CN (1) CN101522716B (cg-RX-API-DMAC7.html)
AU (1) AU2007314522C9 (cg-RX-API-DMAC7.html)
BR (1) BRPI0719953B8 (cg-RX-API-DMAC7.html)
CA (1) CA2664343C (cg-RX-API-DMAC7.html)
CO (1) CO6160305A2 (cg-RX-API-DMAC7.html)
CR (1) CR10689A (cg-RX-API-DMAC7.html)
CY (1) CY1115551T1 (cg-RX-API-DMAC7.html)
DK (2) DK2769992T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2009000058A (cg-RX-API-DMAC7.html)
ES (2) ES2466669T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20140512T1 (cg-RX-API-DMAC7.html)
HU (1) HUE054090T2 (cg-RX-API-DMAC7.html)
IL (1) IL197479A (cg-RX-API-DMAC7.html)
LT (1) LT2769992T (cg-RX-API-DMAC7.html)
MA (1) MA31138B1 (cg-RX-API-DMAC7.html)
ME (1) ME00616B (cg-RX-API-DMAC7.html)
MX (1) MX2009003393A (cg-RX-API-DMAC7.html)
MY (1) MY149079A (cg-RX-API-DMAC7.html)
NI (1) NI200900041A (cg-RX-API-DMAC7.html)
NO (1) NO347180B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ576040A (cg-RX-API-DMAC7.html)
PL (2) PL2069403T3 (cg-RX-API-DMAC7.html)
PT (2) PT2769992T (cg-RX-API-DMAC7.html)
RS (2) RS61650B1 (cg-RX-API-DMAC7.html)
RU (1) RU2445318C2 (cg-RX-API-DMAC7.html)
SI (2) SI2069403T1 (cg-RX-API-DMAC7.html)
TN (1) TN2009000110A1 (cg-RX-API-DMAC7.html)
UA (1) UA98943C2 (cg-RX-API-DMAC7.html)
WO (1) WO2008054606A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200901617B (cg-RX-API-DMAC7.html)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN105884893A (zh) 2002-07-18 2016-08-24 莫鲁斯有限公司 抗体混合物的重组生产
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2395017A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
DK2245064T3 (da) 2007-12-21 2014-10-27 Medimmune Ltd BINDINGSELEMENTER TIL INTERLEUKIN-4-RECEPTOR-ALFA (IL-4Ralfa)
DK2556747T3 (da) 2008-06-27 2021-02-15 Merus Nv Antistofproducerende transgen mus
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
AU2009275227A1 (en) 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
AU2014216019B2 (en) * 2008-10-29 2016-04-21 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to Human IL-4 receptor
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
EP2517556B2 (en) * 2009-07-08 2023-03-22 Kymab Limited Site-Specific Recombination Method, Rodents & Rodent Cells capable of Expressing Chimaeric Antibodies or Chains
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
WO2011097603A1 (en) 2010-02-08 2011-08-11 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
SMT201900241T1 (it) 2010-06-22 2019-05-10 Regeneron Pharma Topi esprimenti una catena leggera ibrida di immunoglobulina con una regione variabile umana
RS55495B1 (sr) * 2010-08-02 2017-04-28 Regeneron Pharma Miševi koji stvaraju vezujuće proteine koji sadrže vl domene
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
CN102830228B (zh) * 2011-06-15 2015-01-21 格诺思博生物科技(上海)有限公司 定量分析循环肿瘤细胞的试剂及试剂盒
JO3412B1 (ar) * 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
MX353931B (es) * 2011-07-11 2018-02-02 Glenmark Pharmaceuticals Sa Anticuerpos que se unen a ox40 y sus usos.
EP3418300B1 (en) 2011-07-18 2020-10-28 Institute for Research in Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
SI3865581T1 (sl) 2011-08-05 2024-12-31 Regeneron Pharmaceuticals, Inc. Miši s humanizirano univerzalno lahko verigo
EP2756004B1 (en) 2011-09-16 2019-12-25 Regeneron Pharmaceuticals, Inc. INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) FOR USE IN REDUCING LIPOPROTEIN(a) LEVELS
CA2846319A1 (en) 2011-09-19 2013-03-28 Kymab Limited Antibodies, variable domains & chains tailored for human use
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
PL2793567T3 (pl) 2011-12-20 2019-09-30 Regeneron Pharmaceuticals, Inc. Myszy z humanizowanym łańcuchem lekkim
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
AU2013204581B2 (en) 2012-03-16 2015-06-25 Regeneron Pharmaceuticals, Inc. Non-human animals expressing pH-sensitive immunoglobulin sequences
RU2644684C2 (ru) 2012-03-16 2018-02-13 Регенерон Фармасьютикалз, Инк. Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения
HUE045537T2 (hu) 2012-03-16 2019-12-30 Regeneron Pharma PH-érzékeny immunglobulin-szekvenciákat expresszáló rágcsálók
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
MX360110B (es) 2012-04-20 2018-10-23 Merus Nv Metodos y medios para la produccion de moleculas de tipo ig.
CN104755495A (zh) 2012-08-21 2015-07-01 赛诺菲 通过施用il-4r拮抗剂治疗或预防哮喘的方法
RU2698907C2 (ru) 2012-09-07 2019-09-02 Ридженерон Фармасьютикалз, Инк. Способы лечения атопического дерматита с помощью антагониста il-4r
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
EP3521312B1 (en) 2013-02-20 2021-04-07 Innate Pharma A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma
WO2014130690A1 (en) * 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
EA201890895A1 (ru) 2013-03-15 2019-02-28 Зинджения, Инк. Мультивалентные и моновалентные мультиспецифические комплексы и их применение
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
PL3010539T3 (pl) 2013-06-21 2020-01-31 Sanofi Biotechnology Sposoby leczenia polipowatości nosa przez podawanie antagonisty il-4r
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
ES2993142T3 (en) 2013-10-01 2024-12-23 Kymab Ltd Animal models and therapeutic molecules
PT3052192T (pt) 2013-10-02 2020-09-24 Medimmune Llc Anticorpos neutralizantes anti-influenza a e suas utilizações
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
KR20170041167A (ko) * 2014-02-19 2017-04-14 조디 베리 마르부르크 단클론성 항체
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
MX376691B (es) 2014-02-28 2025-03-07 Regeneron Pharma Composición farmaceutica que comprende un antagonista de il-4r para tratar una infección cutánea.
WO2015143406A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
ES2872475T3 (es) 2014-03-21 2021-11-02 Regeneron Pharma Animales no humanos que producen proteínas de unión de dominio único
EP3169407A4 (en) 2014-07-15 2018-04-25 Medimmune, LLC Neutralizing anti-influenza b antibodies and uses thereof
WO2016023916A1 (en) 2014-08-12 2016-02-18 Kymab Limited Treatment of disease using ligand binding to targets of interest
WO2016071701A1 (en) 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
KR20230158131A (ko) 2014-11-14 2023-11-17 사노피 바이오테크놀로지 Ｉｌ-4ｒ 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법
AU2016229996A1 (en) * 2015-03-06 2017-09-28 Sorrento Therapeutics, Inc. Antibody therapeutics that bind JAG1
JP2018508224A (ja) 2015-03-19 2018-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗原を結合する軽鎖可変領域を選択する非ヒト動物
CA2981312C (en) 2015-03-30 2023-09-26 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
AU2016239858B2 (en) 2015-04-02 2021-07-01 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
WO2016196470A1 (en) 2015-06-01 2016-12-08 Medimmune, Llc Neutralizing anti-influenza binding molecules and uses thereof
CN106699888B (zh) * 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
TWI870789B (zh) * 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
EP3402513A4 (en) 2016-01-13 2019-10-23 Medlmmune, LLC METHOD FOR THE TREATMENT OF INFLUENZA A
CN109069625A (zh) 2016-02-19 2018-12-21 瑞泽恩制药公司 通过施用il-4r拮抗剂来增强疫苗功效的方法
CN107474134B (zh) * 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
PT3506931T (pt) 2016-09-01 2024-08-21 Regeneron Pharma Métodos de prevenção ou de tratamento da alergia mediante a administração de um antagonista de il-4r
RU2759630C2 (ru) 2016-09-22 2021-11-16 Ридженерон Фармасьютикалз, Инк. Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r
WO2018075378A1 (en) * 2016-10-17 2018-04-26 Vanderbilt University Human respiratory syncytial virus antibodies and methods of use therefor
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
EP3554544A4 (en) 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
CN110431240A (zh) 2017-04-13 2019-11-08 雷杰纳荣制药公司 在编码il33和il1rl1的基因中具有风险等位基因的患者的炎症性肺部疾病的治疗和抑制
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
CN107216388B (zh) * 2017-08-07 2020-05-05 广州泰诺迪生物科技有限公司 一种治疗丙型肝炎病毒药物的制备方法和用途
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
KR102694419B1 (ko) 2017-10-30 2024-08-09 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
CN108373505B (zh) * 2018-04-20 2019-08-20 北京智仁美博生物科技有限公司 抗il-4r抗体及其用途
SG11202009371WA (en) 2018-05-13 2020-10-29 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r inhibitor
CN113101364B (zh) * 2018-05-29 2023-12-01 康诺亚生物医药科技（成都）有限公司 一种自免疫抑制剂的开发和应用
PL3823443T3 (pl) * 2018-07-16 2024-09-23 Regeneron Pharmaceuticals, Inc. Modele gryzoni z chorobą ditra i ich zastosowania
PL3808774T3 (pl) * 2018-08-24 2025-06-23 Jiangsu Hengrui Medicine Co., Ltd. Przeciwciało wiążące ludzki il-4r, jego fragment wiążący antygen i ich zastosowanie medyczne
WO2020096381A1 (ko) 2018-11-09 2020-05-14 아주대학교 산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
CN111514292B (zh) 2018-12-25 2023-06-20 江苏荃信生物医药股份有限公司 抗人白介素4受体α单克隆抗体的制药用途
WO2020180727A1 (en) 2019-03-06 2020-09-10 Regeneron Pharmaceuticals, Inc. Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
WO2020210067A1 (en) * 2019-04-08 2020-10-15 Phanes Therapeutics, Inc. Humanized anti-dll3 chimeric antigen receptors and uses thereof
CN111592597B (zh) * 2019-05-29 2022-04-26 山东博安生物技术股份有限公司 白介素4受体(il-4r)结合蛋白及其用途
US12398212B2 (en) 2019-07-16 2025-08-26 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
CN112279914A (zh) * 2019-07-25 2021-01-29 苏州丁孚靶点生物技术有限公司 Il4ra抗体、基因、载体、宿主细胞和il4ra拮抗剂
CN114173816A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗特应性皮炎的方法
CN114173819A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
JP2023504204A (ja) 2019-12-09 2023-02-01 サノフィ・バイオテクノロジー デジタル的に識別されたｉｌ－４／ｉｌ－１３関連障害を治療する方法
US20230075244A1 (en) * 2020-02-20 2023-03-09 The Feinstein Institutes For Medical Research Agonist antibodies against endoglin and uses thereof
US20230088052A1 (en) 2020-02-21 2023-03-23 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition containing anti-il-4r antibody and use thereof
KR20220147642A (ko) * 2020-02-27 2022-11-03 치아타이 티안큉 파마수티컬 그룹 주식회사 Il4r에 결합하는 항체 및 이의 용도
JP2023520676A (ja) 2020-03-27 2023-05-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒアンタゴニストを投与することによりアトピー性皮膚炎を処置するための方法
JP2023521174A (ja) * 2020-04-10 2023-05-23 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） インターロイキン１受容体アクセサリータンパク質に特異的なバインダーおよびキメラ抗原受容体
CN113527485B (zh) 2020-04-17 2024-11-15 湖南麦济生物技术股份有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用
CN113549151A (zh) * 2020-04-24 2021-10-26 苏州康乃德生物医药有限公司 与人IL-4Rα中特定表位结合的抗体及其应用
IL298257A (en) 2020-05-22 2023-01-01 Regeneron Pharma Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
JP7784412B2 (ja) * 2020-07-17 2025-12-11 ジーアイ イノベーション， インコーポレイテッド Ｉｇｅ ｆｃ受容体アルファサブユニット細胞外ドメイン及び抗ｉｌ－４抗体を含む融合タンパク質並びにその融合タンパク質の使用
KR102697769B1 (ko) 2020-09-14 2024-08-23 아주대학교산학협력단 인터루킨-4 수용체 알파 서브유닛과 인터루킨-5 수용체 알파 서브유닛에 동시에 결합하는 이중특이항체 및 이의 용도
BR112023004020A2 (pt) 2020-10-05 2023-04-25 Sanofi Biotechnology Métodos para tratamento de asma em indivíduos pediátricos através da administração de um antagonista de il-4r
WO2022135441A1 (zh) 2020-12-22 2022-06-30 江苏恒瑞医药股份有限公司 抗il-4r抗体或其抗原结合片段的复合物及医药用途
MX2023008142A (es) * 2021-01-08 2023-09-08 Bristol Myers Squibb Co Anticuerpos y péptidos de unión a antígenos para inhibidores del factor xia y usos de los mismos.
US20220220211A1 (en) 2021-01-08 2022-07-14 Regeneron Pharmaceuticals, Inc. Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
AU2022316939A1 (en) 2021-07-26 2024-03-07 Regeneron Pharmaceuticals, Inc. Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist
TWI876192B (zh) * 2021-08-05 2025-03-11 美商美國禮來大藥廠 人類介白素-4受體α抗體
US20230167171A1 (en) 2021-08-23 2023-06-01 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
US20240343815A1 (en) * 2021-08-26 2024-10-17 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceutical composition of anti-il4r antibody and use thereof
CN119137149A (zh) 2021-10-20 2024-12-13 赛诺菲生物技术公司 用于通过施用il-4r拮抗剂来治疗结节性痒疹的方法
IL313897A (en) 2021-12-30 2024-08-01 Regeneron Pharma Methods for reducing atopic dermatitis by administering an IL-4/IL-13 antagonist
EP4470569A1 (en) 2022-01-29 2024-12-04 Shanghai Shengdi Pharmaceutical Co., Ltd Drug conjugate of glucocorticoid
KR20240167714A (ko) 2022-03-02 2024-11-27 리제너론 파아마슈티컬스, 인크. 고역가 항체의 제조 방법
CA3250514A1 (en) 2022-05-02 2023-11-09 Regeneron Pharmaceuticals, Inc. ANTI-INTERLEUKIN-4 (IL-4R) RECEPTOR ANTIBODIES
CN119497609A (zh) 2022-05-02 2025-02-21 瑞泽恩制药公司 降低脂肪酶活性的方法
AU2023304436A1 (en) 2022-07-08 2025-02-20 Regeneron Pharmaceuticals, Inc. Methods for treating pediatric eosinophilic esophagitis by administering an il-4r antagonist
CN120091829A (zh) 2022-08-29 2025-06-03 赛诺菲生物技术公司 通过施用il-4r拮抗剂治疗慢性诱导性寒冷性荨麻疹的方法
KR20250096792A (ko) 2022-11-01 2025-06-27 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여하여 손 및 발 피부염을 치료하기 위한 방법
AU2023384154A1 (en) 2022-11-23 2025-07-03 Alan IRVINE Methods for improving bone growth by administering an il-4r antagonist
US20240360232A1 (en) 2023-03-22 2024-10-31 Sanofi Biotechnology Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist
TW202502820A (zh) 2023-03-27 2025-01-16 美商再生元醫藥公司 藉由投予ｉｌ—４ｒ拮抗劑治療嗜酸性球性胃腸炎之方法
WO2025075970A1 (en) 2023-10-02 2025-04-10 Regeneron Pharmaceuticals, Inc. Drug delivery device safety system
TW202535934A (zh) 2023-11-02 2025-09-16 美商再生元醫藥公司 利用應力來降低脂酶活性的方法
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
WO2025221640A1 (en) 2024-04-15 2025-10-23 Sanofi Biotechnology Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US809A (en) 1838-06-27 Improved mode of changing the poles of electro-magnets
US7186A (en) 1850-03-19 fetchec
GB8808015D0 (en) * 1988-04-06 1988-05-05 Ritter M A Chemical compounds
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) * 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) * 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
RU2162711C2 (ru) * 1993-09-07 2001-02-10 Смитклайн Бичам Корпорейшн Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP2292665B1 (en) 2000-05-26 2015-07-08 Immunex Corporation Use of interleukin-4 antibodies and compositions thereof
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ATE517855T1 (de) * 2001-11-30 2011-08-15 Biogen Idec Inc Antikörper gegen chemotaktische monozytenproteine
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
TWI356064B (en) * 2003-11-07 2012-01-11 Immunex Corp Antibodies that bind interleukin-4 receptor
AU2004309373A1 (en) * 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
JP2008504806A (ja) 2004-02-27 2008-02-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ−４／ｉｌ−１３特異的ポリペプチドおよびその治療上の使用
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
TW200902555A (en) * 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor

Also Published As

Publication number Publication date
JP2010505418A (ja) 2010-02-25
EP2769992B1 (en) 2020-12-30
CA2664343C (en) 2016-04-26
MX2009003393A (es) 2009-05-11
MA31138B1 (fr) 2010-02-01
US8092802B2 (en) 2012-01-10
BRPI0719953A2 (pt) 2014-04-29
EP2069403A2 (en) 2009-06-17
PT2769992T (pt) 2021-03-11
WO2008054606A2 (en) 2008-05-08
NO347180B1 (no) 2023-06-19
DOP2009000058A (es) 2009-04-30
US20120135010A1 (en) 2012-05-31
SI2769992T1 (sl) 2021-04-30
AU2007314522C9 (en) 2013-08-01
LT2769992T (lt) 2021-04-12
AU2007314522A1 (en) 2008-05-08
US7794717B2 (en) 2010-09-14
US7605237B2 (en) 2009-10-20
HRP20210408T1 (hr) 2021-04-30
EP2769992A3 (en) 2015-01-21
RS61650B1 (sr) 2021-04-29
US8338135B2 (en) 2012-12-25
PL2069403T3 (pl) 2015-08-31
IL197479A (en) 2014-03-31
CR10689A (es) 2009-06-24
WO2008054606A3 (en) 2009-02-05
RS53340B (sr) 2014-10-31
NI200900041A (es) 2011-10-17
NZ576040A (en) 2011-06-30
RU2445318C2 (ru) 2012-03-20
HK1200846A1 (en) 2015-08-14
ES2859825T3 (es) 2021-10-04
MEP11109A (en) 2011-12-20
US20100021476A1 (en) 2010-01-28
ME00616B (me) 2011-12-20
ES2466669T3 (es) 2014-06-10
EP2769992A2 (en) 2014-08-27
EP3845563A3 (en) 2021-11-24
CN101522716B (zh) 2013-03-20
RU2009116608A (ru) 2010-11-10
CN101522716A (zh) 2009-09-02
DK2069403T3 (da) 2014-07-28
CA2664343A1 (en) 2008-05-08
KR101474227B1 (ko) 2014-12-18
NO20091758L (no) 2009-05-04
MY149079A (en) 2013-07-15
HUE054090T2 (hu) 2021-08-30
AU2007314522B2 (en) 2013-02-21
AU2007314522B8 (en) 2013-04-11
TN2009000110A1 (en) 2010-08-19
UA98943C2 (ru) 2012-07-10
AU2007314522A2 (en) 2009-07-02
EP2069403B1 (en) 2014-05-07
CY1115551T1 (el) 2017-01-04
BRPI0719953B1 (pt) 2019-04-24
EP3845563A2 (en) 2021-07-07
AU2007314522C1 (en) 2013-06-27
DK2769992T3 (da) 2021-03-22
HRP20140512T1 (hr) 2014-07-04
PT2069403E (pt) 2014-07-18
KR20090088865A (ko) 2009-08-20
HK1131790A1 (en) 2010-02-05
US20100291107A1 (en) 2010-11-18
SI2069403T1 (sl) 2014-09-30
PL2769992T3 (pl) 2021-08-02
AU2007314522A8 (en) 2013-04-11
IL197479A0 (en) 2011-08-01
BRPI0719953B8 (pt) 2021-05-25
US20080160035A1 (en) 2008-07-03
ZA200901617B (en) 2009-12-30

Similar Documents

Publication Publication Date Title
CO6160305A2 (es) Anticuerpos humanos de alta afinidad para el receptor de il-4 humano
LTC2041177I2 (lt) Didelio giminingumo antikūnai prieš žmogaus IL-6 receptorių
ECSP099404A (es) Anticuerpos humanos contra el ligando 4 de tipo delta humano
NO20084650L (no) Modifiserte humaniserte anti-interleukin-18 antistoffer
NZ706232A (en) Anti-cd3 antibodies and uses thereof
RU2011140509A (ru) Гетеродимерные полипептиды il-17a/f и возможности их лечебного применения
RU2015147300A (ru) Гуманизированные антитела к cxcr5, их производные и их применение
CY1118709T1 (el) Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf
NZ599683A (en) Anti-ilt7 antibody
MX2011008843A (es) Anticuerpos humanizados que se unen a cd19 y sus usos.
CR20120587A (es) Moléculas de unión al antígeno que fijan egfr, vectores que las codifican y uso de las mismas
NZ599140A (en) Antibodies that specifically bind to the epha2 receptor
NZ598202A (en) High affinity human antibodies to human angiopoietin-2
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
WO2007117577A3 (en) High affinity human antibodies to human il-18 receptor
AR073140A1 (es) Anticuerpos anti-il-23r disenados
WO2011064257A3 (de) Monospezifische polypeptidreagenzien
HN2009000575A (es) Anticuerpos humanos de alta afinidad para el receptor de il-4 humano